Kerendia is indicated for the treatment of chronic kidney disease (Stages 3 and 4 with albuminuria) associated with type 2 diabetes in adult patients.
Delay DKD progression with Kerendia® (finerenone)
Kerendia for adult patients with CKD (stage 3 and 4 with albuminuria) associated with T2D
In FIDELIO-DKD there was a sustained reduction in CKD progression* with kerendia compared to placebo
*defined as 1st occurrence of composite of onset of kidney failure or sustained decrease of eGFR≥ 40% from baseline over at least 4 weeks or death due to renal causes. Kidney failure defined as initiation of dialysis for ≥90days or kidney transplantation or eGFR <15ml/min/1.73m2 over ≥4weeks
CKD=chronic kidney disease; MOD=mechanism of disease; MOA=mechanism of action; T2D=type 2 diabetes.
PP-KER-GB-0468 | March 2024
- expand_less